A new clinical trial is underway to test a monoclonal antibody as a treatment for Long Covid.

In this week’s episode Emily Kate Stephens sits down with Dr Nancy Klimas at Nova Southeastern University (NSU), Florida, to discuss the trial alongside the groundbreaking research and integrative care, that is taking place at the Institute for Neuro-Immune Medicine, looking at Long Covid, ME/CFS and other complex conditions.

The trial, a collaboration between Nova Southeastern University and the Schmidt Initiative for Long Covid, will use an AstraZeneca drug, which is already approved for COVID-19 prevention in those with compromised immunity, on 100 patients in a double-blind, randomised controlled trail. And Dr Klimas, a globally recognized expert in immunology and chronic illness, believes that this has the potential to be a curative treatment for the disease in around 40% of patients.

Alongside this new study, we discuss the role of computational modelling and the progress that AI is having in uncovering hidden patterns in chronic disease; the way in which gender differences shape inflammatory responses and treatment strategies; and the critical importance of restorative sleep, nutrition, and anti-inflammatory approaches in improving the lives of patients.

We discuss some of the other studies in which the INIM are involved – the Reboot Study, Microbiome research, probiotics, and the COVIDUP study, along with the power of international collaboration, the challenges of funding and the amazing contribution of patients.

Dr. Nancy Klimas is Director of the Institute for Neuro-Immune Medicine at NSU, and a leading voice in translational research focused on chronic illness, ME/CFS, Gulf War Syndrome, and Long Covid. With decades of experience in immunology and clinical science, Dr. Klimas is a champion for an integrative, personalized approach to patient care.

Make Visible

@visible_health

@visible.health